Skip to content

Drug interactions

Doxorubicin liposomal + Erythromycin

Severity: Moderate

Doxorubicin liposomal and Erythromycin: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Doxorubicin is a substrate of CYP3A4 and P-glycoprotein, both inhibited by erythromycin. Exposure to free doxorubicin may therefore increase, raising the risk of myelosuppression and cardiotoxicity, although the liposomal form has less dependence on these pathways.

What this interaction means in plain words

Doxorubicin liposomal and Erythromycin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Evidence level: Low

Why it happens

Inhibition of CYP3A4 and P-glycoprotein by erythromycin may reduce doxorubicin clearance.

What to do

Monitor blood counts and for signs of doxorubicin toxicity. Consider an alternative antibiotic such as one without CYP3A4 or P-gp inhibition.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Doxorubicin liposomal and Erythromycin, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Doxorubicin liposomal with Erythromycin?

MediHelp rates the interaction as moderate. Doxorubicin liposomal and Erythromycin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Doxorubicin is a substrate of CYP3A4 and P-glycoprotein, both inhibited by erythromycin. Exposure to free doxorubicin may therefore increase, raising the risk of myelosuppression and cardiotoxicity, although the liposomal form has less dependence on these pathways.

How serious is the interaction between Doxorubicin liposomal and Erythromycin?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and for signs of doxorubicin toxicity. Consider an alternative antibiotic such as one without CYP3A4 or P-gp inhibition.

What other medicines interact with Erythromycin?

MediHelp also lists interactions of Erythromycin with, for example, Conivaptan, Dihydroergotamine intranasal, Dihydroergotamine. The full list is on the Erythromycin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in